Untitled

Abstract

There has been some evidence that Behçet's disease (BD) has a significant autoimmune component but the molecular identity of putative autoantigens has not been well characterized. In the initial analysis of the autoantibody profile in 39 Chinese BD patients, autoantibodies to cellular proteins were uncovered in 23% as determined by immunoblotting. We have now identified one of the major autoantibody specificities using expression cloning. Serum from a BD patient was used as a probe to immunoscreen a λZAP expression cDNA library. Candidate autoantigen cDNAs were characterized by direct nucleotide sequencing and their expressed products were examined for reactivity to the entire panel of BD sera using immunoprecipitation. Reactivity was also examined with normal control sera and disease control sera from patients with lupus and Sjögren's syndrome. Six independent candidate clones were isolated from the cDNA library screen and were identified as overlapping partial human kinectin cDNAs. The finding that kinectin was an autoantigen was verified in 9 out of 39 (23%) BD patient sera by immunoprecipitation of the in vitro translation products. Sera from controls showed no reactivity. The significance of kinectin as a participant in autoimmune pathogenesis in BD and the potential use of autoantibody to kinectin in serodiagnostics are discussed.

Juvenile Behсet's Disease: Clinical Observation

“…Кроме того, известно, что аутоиммунные заболевания ассоциируются с молекулами главного комплекса гистосовместимости (Human leukocyte antigens, HLA) II класса, тогда как болезнь Бехчета -с антигеном I класса (HLA-B5) [41]. В пользу аутоиммунной природы болезни свидетельству-ют активация B лимфоцитов и обнаружение аутоантител против поверхностных клеточных антигенов -антиэн-дотелиальных, антилимфоцитарных [42], антител против альфа-тропомиозина, альфа-энолазы, кинектина [43,44] и белка теплового шока (HSP60) [45].…”

Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction

“…This method was originally developed to screen out tumor-associated antigens, which has been used to identify more than 2,300 novel tumor antigens in a public access online database known as the Cancer Immunome Database (CID) [20,21]. And so, it is considered one of the most effective methods for the identification of antigenic targets on a genome scale [22][23][24][25][26][27][28][29][30]. As a result, it has also been used for autoimmune diseases, such as systemic lupus erythematosus, Kawasaki disease, Bechet's disease, and multiple sclerosis in the recent years [22][23][24][25].…”

“…And so, it is considered one of the most effective methods for the identification of antigenic targets on a genome scale [22][23][24][25][26][27][28][29][30]. As a result, it has also been used for autoimmune diseases, such as systemic lupus erythematosus, Kawasaki disease, Bechet's disease, and multiple sclerosis in the recent years [22][23][24][25]. In earlier studies, we used SEREX for atherosclerosis-related diseases and for the identification of antibodies against RPA2 [26], MMP1, CBX1 and CBX5 [27] in CI, and ATP2B4, BMP-1 [28], TUBB2C [29] and SH3BP5 [30] in other atherosclerosis-related diseases.…”

Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction

“…The method was originally developed to screen out tumor-associated antigens, which has been used to identify more than 2,300 novel tumor antigens in a public access online database known as the Cancer Immunome Database [20,21]. And so, it is considered one of the most effective methods for the identi cation of antigenic targets on a genome scale [22][23][24][25][26][27][28][29][30]. As a result, it has also been used for autoimmune diseases, such as systemic lupus erythematosus, Kawasaki disease, Bechet's disease, and multiple sclerosis in the recent years [22][23][24][25].…”

“…And so, it is considered one of the most effective methods for the identi cation of antigenic targets on a genome scale [22][23][24][25][26][27][28][29][30]. As a result, it has also been used for autoimmune diseases, such as systemic lupus erythematosus, Kawasaki disease, Bechet's disease, and multiple sclerosis in the recent years [22][23][24][25]. In earlier studies, we used SEREX for atherosclerosis-related diseases and for the identi cation of antibodies against RPA2 [26], MMP1, CBX1 and CBX5 [27] in CI, and ATP2B4, BMP-1 [28], TUBB2C [29] and SH3BP5 [30] in other atherosclerosis-related diseases.…”